Fingolimod-Associated Intracerebral Lymphoproliferative Disorder. (July 2019)

• Record Type: Journal Article
• Authors: Baharnoori, Moogeh; Mahajan, Rahul; Solomon, Issac H.; Pinkus, Geraldine; Houtchens, Maria
• Is Part Of: American journal of therapeutics. Volume 26:Number 4(2019)
• Publication Date: 2019-07
• Subjects: multiple sclerosis -- disease modifying therapies -- Fingolimod -- lymphoproliferative disorders -- lymphoma; Chemotherapy -- Periodicals; Pharmacology -- Periodicals; 615.58
• DOI: 10.1097/MJT.0000000000000694
• Languages: English
• ISSNs: 1075-2765

Abstract

Abstract : Most epidemiological studies indicate that incidence of cancer in multiple sclerosis patients is lower than general population. However these studies were performed prior to the emergence of disease-modifying therapies (DMTs). The incidence of cancer may be influenced by newer generation DMTs which are immunomodulatory or immunosuppressant. We describe an atypical case of intracerebral plasmacytic lymphoproliferative disorder in a 47 years old patient on fingolimod. As worldwide usage of oral and infusion DMTs increases, heightened clinical suspicion and early recognition of these serious adverse events remain crucial.